Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of ... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.82 | -2.60980267346 | 31.42 | 32 | 27.32 | 142822 | 29.73438875 | DE |
| 4 | -15.36 | -33.4203655352 | 45.96 | 47.66 | 27.32 | 252585 | 35.33001755 | DE |
| 12 | 2.95 | 10.6690777577 | 27.65 | 47.66 | 24.05 | 259413 | 32.99917822 | DE |
| 26 | 10.15 | 49.6332518337 | 20.45 | 47.66 | 17.06 | 228484 | 29.08573938 | DE |
| 52 | 26.065 | 574.751929438 | 4.535 | 47.66 | 3.755 | 327513 | 19.76909613 | DE |
| 156 | 25.755 | 531.578947368 | 4.845 | 47.66 | 2.62 | 193316 | 13.21482737 | DE |
| 260 | 17.4 | 131.818181818 | 13.2 | 47.66 | 1.612 | 152476 | 11.27832337 | DE |
primecomm
3分前
primecomm
4分前
WhiteOwl
4分前
Climb 2 top
4分前
Tamboo
5分前
Tony P
6分前
HyGro
7分前
JusDePomme
7分前
Split T
7分前
barnyarddog
7分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。